Description
Retatrutide Capsules | Triple GLP/GIP/Glucagon Agonist — Metabolic Research
Retatrutide (LY3437943) is a next-generation triple-agonist peptide targeting GLP-1 receptor, GIP receptor, and glucagon receptor simultaneously — a broader mechanism than dual agonists (tirzepatide) or single agonists (semaglutide). Phase II trials demonstrated 24.2% mean body weight reduction at 48 weeks. These capsules (10mg per capsule, 30 capsules) provide an oral research format for metabolic signaling studies.
Mechanism of Action
- GLP-1R agonism — stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through hypothalamic pathways
- GIPR agonism — potentiates insulin secretion in a glucose-dependent manner; contributes to weight loss via CNS GIPR expression
- Glucagon receptor agonism — uniquely increases hepatic fat oxidation and energy expenditure; drives thermogenesis via brown adipose tissue
- Triple-receptor synergy — the combination produces additive-to-synergistic effects exceeding any single-receptor approach
Research Areas
Retatrutide is studied in obesity, type 2 diabetes, NAFLD/NASH, and metabolic syndrome research. The oral capsule format complements injectable vial protocols for pharmacokinetic comparison studies. Compare with Retatrutide vials and Tirzepatide for dual vs. triple agonist comparisons.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. C. Walsh –
Retatrutide capsules for our oral bioavailability study of the GLP-1/GIP/glucagon agonist. Content purity confirmed >99% by our HPLC. Capsule content uniformity excellent. COA detailed.
I. Blackwood –
10mg Retatrutide capsules — capsule weight variation within ±2% of label. Peptide content confirmed by our mass spec. Our oral route pharmacology study benefited from the consistent dosing format.
Y. Tanaka –
Good quality Retatrutide capsules. Content purity verified >98.5%. Capsule uniformity acceptable. COA thorough. Convenient for oral route bioavailability research.